- Home
- KINS vs MXCT Comparison
KINS vs MXCT Comparison
Compare KINS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- MXCT
- Stock Information
- Founded
- KINS 1886
- MXCT 1999
- Country
- KINS United States
- MXCT United States
- Employees
- KINS N/A
- MXCT N/A
- Industry
- KINS Property-Casualty Insurers
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KINS Finance
- MXCT Health Care
- Exchange
- KINS Nasdaq
- MXCT Nasdaq
- Market Cap
- KINS 251.5M
- MXCT 239.2M
- IPO Year
- KINS N/A
- MXCT 2021
- Fundamental
- Price
- KINS $16.30
- MXCT $2.38
- Analyst Decision
- KINS Strong Buy
- MXCT Strong Buy
- Analyst Count
- KINS 1
- MXCT 1
- Target Price
- KINS $6.50
- MXCT $9.00
- AVG Volume (30 Days)
- KINS 428.3K
- MXCT 1.3M
- Earning Date
- KINS 05-08-2025
- MXCT 05-07-2025
- Dividend Yield
- KINS N/A
- MXCT N/A
- EPS Growth
- KINS 5417.04
- MXCT N/A
- EPS
- KINS 1.60
- MXCT N/A
- Revenue
- KINS $169,875,701.00
- MXCT $37,675,000.00
- Revenue This Year
- KINS $40.63
- MXCT $8.82
- Revenue Next Year
- KINS $6.92
- MXCT $21.12
- P/E Ratio
- KINS $10.21
- MXCT N/A
- Revenue Growth
- KINS 18.52
- MXCT N/A
- 52 Week Low
- KINS $4.55
- MXCT $2.10
- 52 Week High
- KINS $22.40
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- KINS 45.69
- MXCT 47.12
- Support Level
- KINS $15.63
- MXCT $2.18
- Resistance Level
- KINS $17.54
- MXCT $2.40
- Average True Range (ATR)
- KINS 1.09
- MXCT 0.13
- MACD
- KINS -0.18
- MXCT 0.02
- Stochastic Oscillator
- KINS 9.90
- MXCT 75.88
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.